



# INTERNATIONAL JOURNAL OF CLINICAL PHARMACOKINETICS AND MEDICAL SCIENCES

Published by Pharma Springs Publication Journal Home Page: https://pharmasprings.com/ijcpms

# Formulation and Evaluation of Phenylephrine Nasal Gels

Shaik Ameer Pasha<sup>1</sup>, Adapa Sowmy<sup>\*2</sup>

<sup>1</sup>Department of Pharmaceutics, Sri Siddhartha Pharmacy College, Ammavarithota, Nuzvid, Kirishna District, Andhra Pradesh, India -521 201.

<sup>2</sup>Department of Pharmaceutical Analysis, Sri Siddhartha Pharmacy College, Ammavarithota, Nuzvid, Kirishna District, Andhra Pradesh, India -521 201

Article History:	Abstract
Received on: 19 Dec 2023 Revised on: 18 Jan 2024 Accepted on: 20 Jan 2024	The primary objective of this study is to develop and evaluate phenylephrine nasal gels, aiming for stable blood levels with lower drug doses through consistent administration, avoiding first-pass hepatic metabolism. Compatibility among the drug, polymers, and lipids was confirmed using FTIR and DSC spectra. Phenylephrine nasal gels were formulated, and their clarity assessed. The gels (ONGF1-ONGF8) had pH values of 6.1-7.2, spreadability of 18.33-21.62 g/cm/sec, and viscosity of
Keywords:	934.2-966.2 centipoises. Drug concentration in these formulations varied from 85.52% to 98.88% indicating accentable medication content. Gel
Nasal gels, Phenylephrine, <i>In vitro</i> diffusion	strength ranged from 64% to 95%. In-vitro drug release of phenylephrine showed 77% to 95% diffusion for ONGF1. The release kinetics followed first order, zero order, Higuchi model, and Korsemeyer-Peppas equations. Kinetic values for all formulations were tabulated. ONGF1 exhibited the most efficient release, with 95% of the drug released within 7 hours, demonstrating a diffusion mechanism followed by non-Fickian transport, adhering to both zero order and Korsemeyer-Peppas models.

\*Corresponding Author

Name: Adapa Sowmy Phone: +91 8187812888 Email: adapa.sowmy@gmail.com

eISSN: 2583-0953 DOI: <u>https://doi.org/10.26452/ijcpms.v4i1.573</u>

Production and hosted by
 Pharmasprings.com
 © 2024 | All rights reserved

#### INTRODUCTION

The word "gels" is a general one that covers semisolid materials with a variety of properties, including rather stiff gelatin slabs, colloidal clay solutions, and specific greases. You can think of a gel as consisting of two interpenetrating phases: a fluid component and a gelling agent. Gels are semisolid substances that consist of either big organic molecules interspersed with liquid or suspensions of small inorganic particles. Within the gel in the first instance, inorganic particles like bentonite create a three-dimensional "house of cards" structure [1]. This is a real two-phase system since the inorganic particles are only scattered throughout the continuous phase and are not soluble. Oversized organic molecules typically reside in solution as flexible chains that are randomly coiled. These molecules' random motion causes them to entangle with one another, whether they are manufactured or natural polymers. The interaction between the inorganic and organic colloidal phase units creates the "structural viscosity" that immobilises the liquid continuous phase [2]. As a result, gels have properties halfway between those of liquids and solids. Gels ought to have characteristics like To shield against microbial attack, it should have the right antimicrobial. Tacky topical gel is not what you want. Sterile ophthalmic gel is required. It ought to be affordable. Gel is used in the pharmaceutical and cosmetic industries for a variety of purposes, including as a vehicle for the delivery of oral medications as well as topical medications that are applied directly to the skin, mucous membranes, or eyes [3].

#### **MATERIALS AND METHODS**

Phenylephrine the gift sample is from Aurovindo Pharma LTD, Hyderabad, and other excipient's such as Hydroxy Propyl Methyl Cellulose is from Himedia Laboratories Pvt. Ltd. Mumbai, Carbopol is from Finar Chemicals Ltd, Ahmedabad, Methylparaben is from Central Drug House Pvt Ltd, New Delhi, and other polymers like Poloxamer 188, Ethanol, Phenyl mercuric nitrate is from S.D. Fine Chem. Ltd. Mumbai.

#### **METHODS**

#### **Pre-Formulation Study**

The physical, chemical, as well as mechanical properties of novel pharmaceutical substances must first be characterised by formulation scientists in order to develop stable, secure, and effective dosage forms. Preformulation is the term for this procedure. Ideally, preformulation should begin early in the process of discovery, allowing for the availability of relevant physical and chemical data to help in the selection of new chemical entities that enter the development process. The present study also takes into account potential interactions with different inert ingredients meant for use in the final dosage form [4].

# FT-IR studies for drug and excipients compatibilities

The preformulation research was completed before the dosage forms were developed. IR spectrum investigations are primarily used to identify chemicals qualitatively, whether they are in their pure form or in combination with polymers and excipients. They also serve as a tool for determining the nature of chemical interactions [5]. I.R. is associated with covalent bonding, hence the spectra can provide intricate details about the composition of molecules. Comparisons between the compounds' spectra and the pure compound were done to prove this hypothesis [6].



# Figure 1 Photography of FTIR spectrophotometer (BRUKER)

# **Differential Scanning Calorimetric**

Distinctive Scanning To look into any changes in the drug's melting point after mixing it with the excipients, calorimetric analysis of both pure pharmaceuticals and the polymers utilised was conducted [7]. Distinctive Scanning With a sample weight of 3 mg, calorimeter curves were acquired using a differential scanning calorimeter with a heating rate of 10°C/min from 25° to 250°C in a nitrogen environment (20 mL/min).

# Formulation of Phenylephrine Nasal Gels

#### **Method of Formulation**

The dispersion process was used to create phenylephrine nasal gels. This approach involved dissolving weighed amounts of polymers, such as HPMC K100 and Carbopol 934, in a known volume of distilled water (Solution-A). The polymer solution was allowed to fully swell for 24 hours following complete dispersion. A predetermined

Ingredients	F1	F2	F3	F4	F5	F6	F7	F8		
Phenylephrine (gms)	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0		
Carbopol (gms)	2	2.5	3	3.0	3.0	3	2.5	2		
HPMC (gms)	3.0	3	2.0	2	2	2.0	3	3.0		
Poloxamer (gms)	1.0	2	2.0	3	1.0	2	2.0	3		
Methyl Paraben (%)	2	2	2	2	2	2	2	2		
Distilled water (ml)	100	100	100	100	100	100	100	100		

Table 1 Formulation data of Phenylephrine Nasal gels

amount of phenolphthalein and Poloxamer 188 were precisely weighed and added to this solution, along with a predetermined amount of phenolphthalein nitrate, which was then dissolved (Solution-B). With the aid of a high-speed magnetic stirrer operating at 500 rpm, solution A and B were completely mixed while being careful to prevent air from becoming trapped. Lastly, distilled water was added to create a uniform gel dispersion. The gel that was created had its pH adjusted to 6.8.



Figure 2 : Eight Formulation of Phenylephrine Nasal gels

# **Evaluation of Nasal Gels**

The drug content, in vitro release tests, as well as physicochemical characteristics of the formulated gel were assessed [8].

# Clarity

Visual inspection against a black and white background was used to assess the clarity of each formulation, and the results were scored as follows: turbid: +, clear: ++, and very clear (glassy): +++.

# **Measurement of Ph**

Using a digtal pH metre, the pH of the phenylephrine gel formulation was measured. 100ml of distilled water was used to dissolve 1 gramme of gel. Using a digital pH metre (Systronics Digital pH metre), the pH of each formulation was measured [9].

# Spreadability

Glass plate apparatus, which was appropriately adjusted in the laboratory as well as employed for investigation, was used to measure the spreadability. Spreadability was evaluated based on the gel's "slip" and drag properties. The spread diameter of one gramme of gel between two glass plates was measured 48 hours after preparation to test the formulations' spreadability. After one minute, the mass of the upper plate was standardised to 125 grammes. To create a consistent gel laver between the slides and to release trapped air, a 1 kg weight was positioned on top of each slide for five minutes. The excess gel around the edges was scraped off. After then, an 80 gramme pull was applied to the top plate [10].

The formula below was used to calculate the spredability.

$$S = \frac{ML}{T}$$



Figure 3 Brookfield Viscometer

# Viscosity

A brook field viscometer (DV II +) was used to measure the viscosity of each gel. Initially, the spindle was submerged in the gel until the spindle's notch made contact with the gel's surface. In the investigation, formulation gels of 100 grammes apiece were employed [11]. Based on the gel's viscosity, spindle number 61 was chosen. It was revolved at 50 revolutions per minute, as well as dial readings were taken until two readings that were similar were obtained.

# Drug content

By carefully weighing one gramme of gel as well as dissolving it in 6.8 pH phosphate buffer76, the drug concentration of the gel was ascertained. With an appropriate dilution, absorbance was measured at 245 nm using a UV visible spectrometer. The slope of a standard curve was used to calculate the drug content [12].

The following equation was used to determine the drug content.

Drug Content = Conversion factor × volume taken × concentration of drug

# **Gelling strength**

The Carbopol & HPMC gel can be penetrated by setting the thermostat to 37°C in a 100 ml measuring cylinder filled with 50 gm of gel [13]. To measure the time in seconds, place the gadget at physiological temperature as well as apply pressure while lowering it five centimetres.





# Figure 4 Measurement of Gel strength

#### In vitro diffusion studies

The produced gel was studied in vitro for diffusion using an egg membrane in a Franz diffusion cell. The receptor compartment was filled with 20 millilitres of phosphate buffer, and 5 grammes of phenylephrine gel was then evenly distributed the membrane [14]. The across donor compartment was kept in touch with a receptor compartment, and the temperature was kept at 37±0.5°C. At predetermined intervals, such as 1, 2, 3, 4, 5, 6 & 7 hours, the receptor's solution pipette out 5 ml of solution from the receptor compartment and immediately replace it with a fresh 2 ml phosphate buffer [15]. The following release order graphs show the in-vitro release profile results for each formulation:

# Kinetic study the Release Order kinetics Mechanism

The in-vitro release profile results for each formulation were plotted using the following data treatment modes [16].

#### Zero order kinetics

Cumulative % of drug release vs. time (Zero-order).

Qt = Qo + Ko t

# **First order kinetics**

Log Cumulative % drug retained vs. time (first-order).

Log Qt = log Qo + K t / 2.303

# Higuchi model

Cumulative percentage of drug release vs. Time squared (Higuchi Matrix Model).

Q t = KH. t1/2

# Korsemeyer and Peppas Release model

Log drug release cumulative percentage V/s log time (Krosmeyer-Peppas Model).

$$F = Mt / M = K.tn$$

A linear plot of drug release against time will have an intercept equal to log K and a slope of n.

With n = 0.5, pure fickian diffusion is indicated.

The values of n = 0.5-1 or 0.45-0.89 suggest nonfickian diffusion. i.e., the spectrum of drug release and solvent penetration rates is shared. Adapa Sowmy Shaik and Ameer Pasha Int. J. of Clin. Pharm. Med. Sci. 2024; 4(1): 1-10

Description	Method Evaluated	0 <sup>th</sup> day	1 <sup>st</sup> week	2 <sup>nd</sup> week
Phenylephrine	Physical Evaluation	White Crystalline	White Crystalline	White Crystalline
		powder	Powder	powder

#### **Table 2 Physical Evaluation Method of Drug**

#### Table 3 Interpretation data of IR spectra Phenylephrine

IR absorption bands	(cm-1)	Bond	Functional group
Observed peak	Characteristic peak		
3691.88	3000-3700	ОН	
2360.95	2100-2660	C=C	Alkynes
2345.52	2100-2660	C=C	Alkynes
1452.45	1330-1540	NO <sub>2</sub>	Nitro compounds
1413.87	1330-1540	$NO_2$	Nitro compounds
1377.22	1220-1540	NO <sub>2</sub>	Nitro compounds
1315.50	600-1500	СН	Alkane
1155.40	600-1500	СН	Alkane
	1000-1300	СО	Alcohols
1116.82	600-1500	СН	Alkane
	1000-1300	СО	Alcohols

Zero order release is indicated by n = 0.89 or 1, and it can occur when drug diffusion is faster than the steady-state rate of solvent-induced relaxation.

#### **RESULTS AND DISCUSSION**

#### **Preformulation Studies**







#### Figure 6 DSC curve of Phenylephrine

#### **Differential Scanning Calorimetry**

The Phenylephrine of endothermic peak was found to be  $194.56^{\circ}$ C.

#### **Evaluation of Phenylephrine Nasal Gels**

**Clarity:** Gels containing carbopol were observed to be translucent and dazzling. It was discovered that polxamer and HPMC gels were translucent and white viscous. Table 4 indicates that there were no particles present in any of the gels.

#### pН

All produced gel formulations (ONGF1-ONGF8) had pH values between 6.2 and 6.9, as indicated by table 4 as well as figure 7.



# Figure 7 pH of Phenylephrine Nasal gels

# Spreadability

The spreadability rating shows how easily a modest amount of shear can spread the gel. The gels' spreadability ranged from 19.51 to 33.91 g.cm/sec, as indicated by Table 4 and Figure 8.



Figure 8 Spreadability of Phenylephrine Nasal gels

# Viscosity measurement

Using a Brookfield viscometer, the viscosity of many formulations of phenylephrine gels was determined. All gel systems that were formulated had their rheological behaviour examined. Consistency in a gel system is determined by the ratio of the solid to liquid fraction, which creates the structure. As indicated in table 4 and figure 9, the viscosity of the different gel formulations was found to range from 8628 to 9622 centipoises.



# Figure 9 Viscosity of Phenylephrine Nasal gels

All manufactured gel formulations were found to have a drug concentration ranging from 78.53 to 98.56 percent. It was determined that the formulations' % medication content was acceptable. Methods used for gel compositions were therefore determined to be appropriate, as displayed in Figure 10 and Table 4.

6



Figure 10 Drug Content of Phenylephrine Nasal gels

# Gel strength

It was discovered that the gel strength of every manufactured gel formulation fell between 69 and 96%. The formulations' % medication content was judged to be acceptable. As a result, techniques used for gel compositions were determined to be appropriate, according to table 4 as well as figure 11.



Figure 11 Gel strength of Phenylephrine Nasal gels





Formulation code	Clarity	рН	Spread ability(g.cm/sec)	Viscosity (cps)	% Drug Content	Gelling strength (sec)
ONGF1	+++	6.1	21.62	934.2	98.88	64±2
ONGF2	+	8.2	23.12	958.8	96.55	66±4
ONGF3	++	7.4	26.44	965.2	92.44	72±3
ONGF4	+	6.6	28.72	844.3	89.66	85±5
ONGF5	++	7.5	16.76	868.9	94.76	71±2
ONGF6	+	8.2	24.22	822.8	83.33	78±5
ONGF7	+	8.1	22.48	813.8	84.68	82±3
ONGF8	+	7.2	18.33	966.2	85.52	95±3

 Table 4 Evaluation parameters of Phenylephrine nasal gel

Table	5 In-vitro	diffusion	drug release	of Phenyle	phrine of nasal	gels
			0			0

Time	Percentage amount of drug release										
(Hrs)	ONGF1	ONGF2	ONGF3	ONGF4	ONGF5	ONGF6	ONGF7	ONGF8			
1	$41 \pm 0.2$	$47 \pm 0.2$	$41 \pm 0.5$	$31 \pm 0.3$	$21 \pm 0.3$	$22 \pm 0.5$	$22 \pm 0.2$	22 ±0.3			
2	$42 \pm 0.3$	$43 \pm 0.5$	$43 \pm 0.5$	$47 \pm 0.6$	$33 \pm 0.4$	$38 \pm 0.5$	36 ±0.4	27 ±0.5			
3	$48 \pm 0.5$	$53 \pm 0.3$	$57 \pm 0.1$	$61 \pm 0.2$	$45 \pm 0.6$	$53 \pm 0.7$	48 ±0.5	37 ±0.7			
4	$55 \pm 0.2$	$61 \pm 0.2$	68 ± 0.5	63 ± 0.3	$55 \pm 0.8$	$63 \pm 0.7$	54 ±0.7	$45 \pm 0.4$			
5	$76 \pm 0.1$	$71 \pm 0.5$	$77 \pm 0.3$	$74 \pm 0.5$	$71 \pm 0.2$	$75 \pm 0.8$	62 ±0.3	57 ± 0.2			
6	$78 \pm 0.5$	82 ± 0.6	86 ± 0.6	$82 \pm 0.4$	77 ± 0.3	$81 \pm 0.4$	65 ±0.6	72 ± 0.8			
7	94 ± 0.6	92 ± 0.7	93 ± 0.2	93 ± 0.2	$81 \pm 0.5$	$88 \pm 0.2$	77 ±0.4	$83 \pm 0.7$			
8	93 ± 0.4	91 ± 0.5	91 ± 0.3	92 ± 0.2	$82 \pm 0.4$	87 ± 0.3	76±0.3	82 ± 0.6			

	· ··			1	<b>n</b> 1	ONOD4
Table 6	In-vitro	drug releas	e kinetics	data foi	r Formulatioi	1 ONGET

Zero order		First order		Higuchi's d	ata	Korsmeyer-Peppas data		
Time	04 CDD	Time	Log % CD	SQR	04 CDD	LogTimo		
(h)	%) CDK	(h)	Remaining	Time	% CDK	Log Time	LUG % CDK	
0	0	0	2	1	0	0	0	
1	41	1	1.75	1.72	41	0.46	1.61	
2	42	2	1.74	3	42	0.59	1.62	
3	46	3	1.71	2.22	46	0.68	1.66	
4	55	4	1.63	2.43	55	0.76	1.73	
5	77	5	1.33	2.63	77	0.76	1.73	
6	78	6	1.31	2.81	78	0.84	1.88	
7	94	7	0.68	2.81	951	0.91	1.90	

#### In vitro drug diffusion studies

The Franz diffusion cell was used as the diffusion test device for in vitro drug release investigations. According to these release investigations, the release sequence was discovered to be as indicated in Table 5.

# **Kinetic Models Data Analysis**

First order, zero order, Higuchi model, as well as Korsemeyer-Peppas drug release kinetic equations were fitted to the diffusion data. Every formulation (ONGF1, ONGF2, ONGF3, ONGF4, ONGF5, ONGF6, ONGF7, & ONGF8) had its kinetic values obtained and tabulated accordingly. The Higuchi, Zero order, First order, and Korsemeyer-Peppas models' cumulative drug release percentage versus time (hours), log cumulative drug remaining percentage versus time (hours), cumulative drug release percentage versus square root of time, and log cumulative drug release percentage versus log time are plotted against these graphs.

Order Of	Zero order		First Order		Higuchi		Korse Meyer Peppass		Mechanism	
Process	R <sup>2</sup>	slope	R <sup>2</sup>	slope	R <sup>2</sup>	slope	R <sup>2</sup>	N		
ONGF1	0.9055	11.475	0.8277	0.150	0.874	29.805	0.8968	0.822	Non- Fickian	

**Table 7 Drug Release Kinetics of Phenylephrine Nasal Gels** 



Figure 13 The profiles of formulations for in vitro drug release ONGF-1-ONGF8







Korsemeyer-Peppas formulations for F1, F2, F3, F4, F5, F6, F7, and F8 were used; the correlation coefficients were R2=0.8968, 0.6042, 0.8592, 0.8095, 0.9721, 0.9706, 0.3191, and 0.2692, in that order. The ONGF1 formulation shows a diffusion release mechanism followed by non-fickian transport. It adheres to both the Zero order as well as Korsmeyer-Peppas models.





The goal of the current study was to formulate and assess cold-pressed phenylephrine nasal gels.

0.5

LOG TIME

1

0.5

0

0

There was no chemical interaction during the encapsulation process, according to the FTIR and DSC measurements. The transparency of the phenylephrine nasal gel evaluation using the clarity test will be ensured. All gel formulations that were produced (ONGF1-ONGF8) had PH values between 6.1 and 7.2. The gels' spread ability ranged from 21.62 to 18.33 g/cm/sec. The range of viscosity of several gel formulations was found to be between 934.2 as well as 966.2 centipoises. All prepared gel formulations were found to have a drug concentration ranging from 98.88 to 85.52%. It was determined that the formulations' % medication content was acceptable. It was discovered that the gel strength of every manufactured gel formulation ranged from 64 to 95%. 95% of the drug was released within 7 hours in the case of the delayed in-vitro release of phenylephrine. The ONGF 1 formulation is the best of the eight; it shows a diffusion release mechanism followed by non-fickian transport and follows both the Zero order as well as Korsemever-Peppas models.

#### ACKNOWLEDGMENT

The authors are thankful to the Principal and Management of Sri Siddhartha Pharmacy College, Nuzvid for providing the necessary infrastructure and facilities to conduct this research work.

# **Conflict of Interest**

The authors declare no conflict of interest, financial or otherwise.

# **Funding Support**

The authors declare that they have no funding for this study.

# REFERENCES

- [1] D H Shastri, H T Dodiya, A Bhanupriy, and P Shelat. Formulation Development and Evaluation of a Gastro retentive oral gel of Cefuroxime Axetil. Journal of Young Pharmacists, 8(4):324-329, 2016.
- [2] T D Nandgude, R Thube, N Jaiswal, and P T Deshmukh. Formulation and evaluation of ph induced Topical gel of salbutamol sulphate. International journal of pharmaceutical sciences and nano technology, 1(2):2008.
- [3] R B Saudagar, S B Deore, and S B Gondkar. Formulation Development and Evaluation

of Topical Gel of Lisinopril Dihydrate. Scholars Academic Journal of Pharmacy, 5(7):277-283, 2016.

- [4] K l Agarwal, N Mehta, A Namdev, and A K Gupta. In-Situ Gel Formation for topical Drug Delivery System. Asian Journal of Biomedical and Pharmaceutical Sciences, 1(4):01-07, 2011.
- [5] V V Prasanth, D G T Parambi, and S Ranjan. Formulation and evaluation of intra Topical gel of Levofloxacin. European journal of pharmaceutical and medical research, 4(12):249-253, 2017.
- [6] R A Shah, M R Mehta, D M Patel, and C N Patel. Design and optimization of mucoadhesive Topical gel containing sodium cromoglycate using factorial design. Asian Journal of Pharmaceutics, 5(2):65-74, 2011.
- [7] R Arun Raj, and A Murali. Formulation and Evaluation of Curcumin Loaded Transferosomal Nasal In-Situ Gel for Alzheimer's Disease. A Journal of Drug Formulation, Development and Production, 6(2):18-31, 2019.
- [8] D G Umalkar, J K Dhondkar, G Y Dama and S J Bidkar. Formulation and evaluation of Topical in-situ gel of bupropion hydrochloride. World journal of pharmacy and pharmaceutical sciences, 4(1):934-943, 2015.
- [9] R B Saudagar, and M M Kulkarni. Formulation Development and Evaluation of In-Situ Nasal Gel of Ziprasidone Hydrochloride. International journal of universal pharmacy and bio sciences, 10(9):195-211, 2017.
- [10] P R PATIL, V K SALVE, R U THORAT, S R SHAHI. Formulation and evaluation of ionsensitive in-situ Topical gel of Zolmitriptan. International journal of pharmacy and pharmaceutical sciences, 7(2):554-559, 2015.
- [11] S P sherafudeen, and P V Vasantha. Development and evaluation of Topical gel formulations of loratadine. Research in pharmaceutical sciences, 10(6):466–476, 2015.
- [12] H S Mahajan , and S Gattani. In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits.

International journal of advances in pharmaceutical analysis, 17(1):19-27, 2010.

- [13] M Priyanka, F S Dasankoppa, H N Sholapur, NGN Swamy and V Sajjanar. Design, characterization and evaluation of topical liposomal gels formulations of venlafaxine hydrochloride for brain targeting. Indian drugs, 53(1):25-31, 2016.
- [14] M Kurakula, C Srinivas, N Kasturi, and P V Diwan. Formulation and Evaluation of Prednisolone Proliposomal Gel for Effective Topical Pharmacotherapy. International Journal of Pharmaceutical Sciences and Drug Research, 4(1):35-43, 2012.
- [15] A Nerella, P Dontha, A Uppuluru and S K Konda. Formulation and evaluation of insitu muco -adhesive Topical gel of Montelukast sodium. Der Pharmacia Sinica, 5(2):1-8, 2014.
- [16] M Tejaswini and A Seetha Devi.
   Formulation and evaluation of Topical gel of Phenylephrine hydrochloride.
   International Journal of Drug Research and Technology, 6(2):64-78, 2016.

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial- Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.



© 2024 Pharma Springs Publication